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Background: For patients presenting with ST segment elevation myocardial infarc-
tion (STEMI), door-to-balloon (or ﬁrst device) time (D2B) is effected by multiple
patient and system-based factors. We hypothesized that fellow and/or catheterization
(cath) team in-hospital call would result in decreased D2B time.
Methods: We collected data from our hospital’s STEMI database and the electronic
medical record. Patients were divided into two groups based on whether the fellow
was taking home or in-hospital call. A subgroup analysis included whether the cath lab
team was in-hospital or at home. The mean difference in D2B between the groups was
calculated using independent T test and one-way ANOVA test.
Results: From June 1, 2009 to June 30, 2013, a total of 313 patients presented with
STEMI and underwent emergency coronary angiography: 186 presented when the
fellow was taking home call, and 127 presented while the fellow was taking in-
hospital call. Mean D2B was signiﬁcantly lower (44 min vs. 56 min, p< 0.01) when
the fellow was taking in-hospital call (Figure 1). In a subgroup analysis, D2B times
were highest when the fellow and cath team were home, and lowest when both the
fellow and the cath lab team were in-hospital (69 min vs. 52 min vs. 40 min)
(Figure 2).
Conclusions: D2B times may be improved with a 24 hour in-hospital call team.
Whether this translates into better clinical outcomes needs to be addressed.TCT-32
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intervention for ST segment elevation myocardial infarction
Akhil Parashar1, Shikhar Agarwal1, Aatish Garg1, Amar Krishnaswamy1,
Kanhaiya L. Poddar1, Stephen Ellis2, E. Murat Tuzcu3, Samir Kapadia1
1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, United States,
3Cleveland Clinic Foundation, Cleveland, United States
Background: There is a paucity of evidence on the impact of angiotensin converting
enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on long-term
outcomes in patients with ejection fraction (EF) >40% after primary percutaneous
coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STE-
MI).We compared long-term all-cause mortality between patients with LVEF > 40%
discharged on ACEi/ARB with patients who were discharged on neither of these
agents.
Methods: Patients presenting with STEMI to our catheterization laboratory between
2003 and 2011 were included. Patients were excluded if they had left ventricular
ejection fraction (LVEF) < 40% or chronic kidney disease or hypotension. Long-
term mortality and discharge medications were determined using the Social Se-
curity Death Index and electronic medical record review, respectively. Unadjusted
and adjusted survival analyses were performed using Kaplan-Meir and Cox
proportional hazards modeling respectively with all-cause mortality as primary
outcome.
Results: A total of 988 patients were included. The median follow up duration was 4.6
years. Kaplan-Meier analysis showed no signiﬁcant difference in long-term mortality
in patients discharged on ACEi/ARB compared to those who were not discharged on
these medications. In addition, multivariable Cox proportional hazard modeling
(ﬁgure) failed to demonstrate any beneﬁcial effect of ACEi/ARB similar to Kaplan-
Meir analysis [HR (95%CI): 0.88 (0.57-1.36)].B10 JACC Vol 64/11/Suppl B jConclusions: We found no signiﬁcant beneﬁt in long-term mortality with the use of
ACEi/ARB in patients with LVEF>40% after pPCI for STEMI.
TCT-33
Large Versus Standard Thromboaspiration Device Comparison in Patients
Undergoing Primary Percutaneous Coronary Intervention
Fernando Rivero-Crespo1, Jorge-Andrés Restrepo2, Javier Cuesta3,
Teresa Bastante-Valiente4, Amparo Benedicto4, Guillermo Diego-Nieto4,
Fernando Alfonso2
1Hospìtal Universitario de la Princesa, Madrid, Spain, 2Hospital Universitario de la
Princesa, Madrid, Spain, 3Hospital Universitario de la Princesa, Madrid, MS,
4Hospital Universitario de la Princesa, Madrid, España
Background: Thrombus aspiration (TA) during primary PCI has demonstrated to be of
value in reducing infarct size. In “in vitro” studies larger caliber devices have
demonstrated a better aspiration power. Whether this difference may translate into a net
clinical beneﬁt in this setting remains unsettled. We sought to compare the efﬁcacy of
7F vs the 6F TA devices (Export, Medtronic Inc.) in patients undergoing primary PCI.
Methods: Prospective observational study with consecutive inclusion of patients
presenting with STEMI referred to our institution for primary PCI. After crossing the
lesion with a guidewire, an attempt to TA was performed in every patient. The se-
lection of a 6F or 7F TA device was left at the operator’s discretion. The primary study
endpoint was the occurrence of TA success, deﬁned as an angiographic improvement
in TIMI ﬂow on the infarct-related artery of at least 1 TIMI grade.
Results: A total of 403 consecutive STEMI patients, 240 treatedwith the 7F (77%) and 70
(23 %) with the 6F device were included. Clinical and demographic characteristics of the
study population are shown in Table 1. Successful access to the lesion with the TA device
was achieved in a 87% vs 94% of patients in 7F and 6F groups respectively (p¼NS). TA
success was achieved in a signiﬁcantly higher percentage of patients in the 7F-device
group (83%) as comparedwith the 6F-device group (71%), (OR: 2.03 , 95%CI 1.19-3.77;
p¼ 0.03).The percentage of patients with a ﬁnal TIMI 3 ﬂow was similar in both groups,
with 93.3% and 95.7 % for the 7F and 6F devices respectively (p ¼ 0.30).ST-segment
elevation resolution 60 min after the intervention was also similar in both groups (68% vs
62 % in the 7F and 6F groups respectively; p ¼ 0.34). There was no acute coronary
complication associated with the use of TA in any group.At 12 months of clinical follow-
up the occurrence of all cause mortality (5% vs 8%, p¼ 0.36) was similar in both groups.
Conclusions: In patients with STEMI undergoing primary PCI the use of a 7F-TA
device appears to be associated with a higher TA success rate as compared with the
use of a 6F device. However, both devices are associated with similar early and late
clinical outcomes.
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Background: Difference in long-term mortality between ST-segment elevation
myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarctionSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM(NSTEMI) have been demonstrated in a few studies. It remains unclear in the drug-
eluting stent (DES) era.
Methods: We consecutively enrolled acute myocardial infarction (AMI) patients who
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnver-
gent REgistry of cAtholic and chonnAm university for AMI) from January 2004 to
December 2009. Of 4,748 AMI patients, 2,607 and 1,617 patients who treated with
only DES were diagnosed with STEMI and NSTEMI, respectively. The primary
endpoint is 30-day all-cause mortality and mortality from 31 days to 5 years. We
performed landmark analysis at 30 days.
Results:Median follow up duration was 43.3 months (interquartile range 29.4 to 59.7
months). All-cause mortality rate at 30 days was higher in STEMI (3.6%; 94 patients)
than NSTEMI (2.4%; 39 deaths; P¼0.031). On the other hand, mortality from 31 days
to 5 years was higher in NSTEMI (17.4% vs. 13.7%; 273 deaths vs. 343 deaths;
P¼0.001). After adjustment with clinical and angiographic characteristics, STEMI is
associated with 30-day mortality (hazard ratio (HR) 1.54, 95% conﬁdence interval
(CI) 1.06-2.25, P¼0.025) and NSTEMI is independent predictor for mortality from 31
days to 5 years (HR 1.26, 95% CI 1.07-1.48, P¼0.006).Conclusions: STEMI was associated with a higher risk of short-term mortality, but
NSTEMI was associated with a higher risk of long-term mortality in the DES era.
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Background: While clinical outcomes undoubtedly favor primary percutaneous
coronary intervention (PPCI) over thrombolysis for ST-elevation Myocardial Infarc-
tion (STEMI), there is paucity of data on the optimal length of hospital stay.
Methods: Between Jan. 2008 and Sep. 2009, a total of 4,549 STEMI patients enrolled
in the Korea Acute Myocardial Infarction Registry(KAMIR) who underwent PPCI
and survived to hospital discharge, were grouped according to the length of stay in
hospital: Group I (short stay, 3 day, n¼809); Group II (medium stay, 4-6 days,
n¼2,263); Group III (long stay, 7 days, n¼1,477). We investigated major adverse
cardiac events (MACEs) at 1, 6, and 12 months and independent predictors of long
stay in hospital.
Results: Group III were signiﬁcant older age (62.8 vs. 63.3 vs. 66.9 years, p< 0.001),
more female (18.3, 22.3, 30.2%, p< 0.001), lower body mass index (BMI) (24.8, 24.2,
23.7, p¼0.001), higher Killip classII (19.9, 26.1, 41.3%, p< 0.001), higher three
vessel disease (14.4, 16.8, 19.6%, p¼0.005), higher prevalence of complication during
PPCI (4.1, 7.7, 18.5%, p< 0.001); higher level of NT-proBNP, lower LV ejection
fraction(EF) (p< 0.001). There were no signiﬁcant difference of MACE at 1, 12
months between Group I, II and III (1 month MACE: 2.4 vs. 1.7 vs. 2.3%, p¼0.475;
12 months: 3.4, 5.6, 3.9%, p¼0.262). In multivariate analysis, independent predictors
of long stay (7 days) in hospital were advanced Killip class II (odds ratio [OR]
1.752; 95% CI, 1.361-2.255, p< 0.001), higher complication rates during PPCI (OR
2.479; 95% CI, 1.737-3.537, p< 0.001), EF < 35% (OR 1.853; 95% CI, 1.142-3.007,
p¼0.013), creatinine > 2.5 mg/dL (OR 3.900; 95% CI, 1.053-14.441, p¼0.042),
higher troponin I (OR 1.698; 95% CI, 1.353-2.132, p< 0.001) and NT-pro BNP
levels(OR 1.946; 95% CI, 1.468-2.580, p< 0.001).
Conclusions: Short length of stay in hospital for low-risk and uncomplicated patients
was similar clinical outcomes and prognosis compared with medium, long stay after
PPCI for STEMI during a 12-month clinical follow-up.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-36
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Background: We evaluated the impact of normal versus high presenting BP on
clinical outcomes and cardiac function in patients with acute ST-elevation myocar-
dial infarction (STEMI) treated with primary percutaneous coronary intervention
(PPCI).
Methods: A total of 12,234 STEMI patients treated with primary percutaneous
coronary intervention (PPCI) were compared according to normal (systolic BP
>90 mmHg and 139 mmHg) versus high (systolic BP 140 mmHg) presenting
BP.
Results: Patients with normal presenting BP (n ¼ 7,647, 62.5%) were associated with
signiﬁcantly higher in-hospital mortality (4.3 vs. 1.8%, p < 0.001), particularly in
patients with prior hypertension, when compared to patients with high presenting
BP (n ¼ 4,587, 37.5%). Patients with normal presenting BP showed higher incidence
of cardiac death (5 vs. 2.6%, p < 0.001) and the composite of major adverse
cardiac events (MACE, deﬁned as all-cause death, myocardial infarction, or re-
vascularizations; 12.2 vs. 10.1%, p < 0.001) at one-year when compared to patients
with high presenting BP. Left ventricular ejection fraction was signiﬁcantly lower in
patients with normal presenting BP at baseline and follow-up (50.7 vs. 51.9%, p <
0.001; 53.6 vs. 54.7%, p ¼ 0.011, respectively). Normal presenting BP was associated
with increased risk of in-hospital mortality (adjusted OR 2.472, CI 1.681-3.635, p <
0.001) in logistic regression analysis. However, it was not associated with cardiac
death (adjusted HR 1.02, CI 0.671-1.55, p¼0.927) and the composite of MACE
(adjusted HR 0.887, CI 0.693-1.135, p ¼ 0.34) at one-year in Cox proportional hazard
regression analysis.
Conclusions: Normal presenting BP, particularly in patients with prior hyper-
tension, was associated with increased in-hospital mortality and lower cardiac
function in STEMI patients treated with PPCI when compared to high presenting
BP. However, outcomes were not different in both groups of patients at one-year
although cardiac function was persistently lower in patients with normal pre-
senting BP.
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Background:We compared the efﬁcacy and safety of sirolimus-eluting stents (SESs),
everolimus-eluting stents (EESs), biodegradable polymer stent (BP-DESs), and
endothelial progenitor cell capture stents (EPCCSs).
Methods: From the IRIS-DES registry, we identiﬁed 1517 patients treated using PCI
with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼ 300), and EPCCSs (N¼440)
in ST-elevation myocardial infarction (STEMI). Major adverse cardiac events
(MACE) were deﬁned using composite of death, myocardial infarction, and target
vessel revasularization at 24 months.
Results: At 2 years, there was no difference in the incidence of MACE (8.5% in
SESs, 9.9% in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death
(5.0% in SESs, 4.3% in EES, 4.4% in BP-DES, and 6.2% in EPCCS, P ¼ 0.718),
MI (0.6% in SESs, 1.6% in EES, 1.5% in BP-DES, and 1.5% in EPCCS, P ¼
0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5% in
EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in any
revascularization, but no signiﬁcantly statistical difference (6.6% in SESs, 9.1% in
EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313). The cumulative rates of
deﬁnite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BP-DESs, and
1.6% in EPCCSs (P ¼ 0.239).
Conclusions: The 4 different DESs showed no signiﬁcant difference in clinical
outcome at 2-year follow-up in patients with STEMI.ute Myocardial Infarction B11
